Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2014

01-11-2014 | Original Article

Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome in children with hematological malignancies

Authors: Daisuke Suzuki, Ryoji Kobayashi, Akihiro Iguchi, Hirozumi Sano, Kenji Kishimoto, Kazue Yasuda, Kunihiko Kobayashi

Published in: International Journal of Hematology | Issue 5/2014

Login to get access

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder characterized by seizures, altered mental status and visual disorders, along with characteristic radiological findings. It is strongly related to hypertension induced by steroids and other immunosuppressive agents. There are an increasing number of reports regarding PRES arising during the course of chemotherapy for hematological malignancies. To clarify the risk factors for this phenomenon, we retrospectively analyzed pediatric patients undergoing treatment for hematological malignancies. Of 161 patients, six patients (3.7 %) developed PRES with characteristic clinical and radiographic findings. Univariate analysis revealed that tumor lysis syndrome (TLS) was a significant risk factor for the onset of PRES. TLS is a significant risk factor for the development of PRES in pediatric patients receiving chemotherapy for hematological malignancies.
Literature
1.
Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500.PubMedCrossRef
2.
3.
Pavlakis SG, Frank Y, Kalina P, Chandra M, Lu D, et al. Occipital-parietal encephalopathy: a new name for an old syndrome. Pediatr Neurol. 1997;16:145–8.PubMedCrossRef
4.
Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol. 2004;77:72–6.PubMedCrossRef
5.
Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122:128–34.PubMedCrossRef
6.
7.
Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998;19:415–7.PubMed
8.
Hwang TL, Yung WK, Estey EH, Fields WS. Central nervous system toxicity with high-dose Ara-C. Neurology. 1985;35:1475–9.PubMedCrossRef
9.
Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesumaga L, et al. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol. 2001;24:145–8.PubMedCrossRef
10.
Shin RK, Stern JW, Janss AJ, Hunter JV, Liu GT. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology. 2001;56:388–91.PubMedCrossRef
11.
Suminoe A, Matsuzaki A, Kira R, Fukunaga N, Nishio T, Hoshina T, et al. Reversible posterior leukoencephalopathy syndrome in children with cancers. J Pediatr Hematol Oncol. 2003;25:236–9.PubMedCrossRef
12.
Lucchini G, Grioni D, Colombini A, Contri M, De Grandi C, Rovelli A, et al. Encephalopathy syndrome in children with hemato-oncological disorders is not always posterior and reversible. Pediatr Blood Cancer. 2008;51:629–33.PubMedCrossRef
13.
Antunes NL, Small TN, George D, Boulad F, Lis E. Posterior Leukoencephalopathy syndrome may not be reversible. Pediatr Neurol. 1999;20:241–3.PubMedCrossRef
14.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767–78.PubMedCrossRef
15.
Lucchini G, Grioni D, Colombini A, Contri M, De Grandi C, Rovelli A, et al. Encephalopathy syndrome in children with hemato-oncological disorders is not always posterior and reversible. Pediatr Blood Cancer. 2008;51:629–33.PubMedCrossRef
16.
Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013;88:301–5.PubMedCrossRef
17.
Cordelli DM, Masetti R, Bernardi B, Barcia G, Gentile V, Biagi C, et al. Status epilepticus as a main manifestation of posterior reversible encephalopathy syndrome after pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2012;58:785–90.PubMedCrossRef
18.
de Laat P, Te Winkel ML, Devos AS, Catsman-Berrevoets CE, Pieters R, van den Heuvel-Eibrink MM. Posterior reversible encephalopathy syndrome in childhood cancer. Ann Oncol. 2011;22:472–8.PubMedCrossRef
19.
Tsukamoto S, Takeuchi M, Kawajiri C, Tanaka S, Nagao Y, et al. Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy. Int J Hematol. 2012;95:204–8.PubMedCrossRef
20.
Greenwood MJ, Dodds AJ, Garrick R, Rodriguez M. Posterior leukoencephalopathy in association with the tumour lysis syndrome in acute lymphoblastic leukemia-a case with clinicopathological correlation. Leuk Lymphoma. 2003;44:719–21.PubMedCrossRef
21.
Ozkan A, Hakyemez B, Ozkalemkas F, Ali R, Ozkocaman V, Ozcelik T, et al. Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy. Neuroradiology. 2006;48:887–92.PubMedCrossRef
22.
Kaito E, Terae S, Kobayashi R, Kudo K, Tha KK, Miyasaka K. The role of tumor lysis syndrome in reversible posterior leukoencephalopathy syndrome. Pediatr Radiol. 2005;35:722–7.PubMedCrossRef
23.
Hijiya N, Metzger ML, Pounds S, Schmidt JE, Razzouk BI, Rubnitz JE, et al. Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatric Blood Cancer. 2005;44:63.PubMedCrossRef
24.
Olgar S, Yetgin S, Cetin M, Aras T. Can renal leukemic infiltration cause hypertension in children? J Pediatr Hematol Oncol. 2006;28:579–84.PubMedCrossRef
25.
Erten N, Saka B, Caliskan YK, Besisik S, Karan MA, Tasciogu C. Acute renal failure due to leukaemic infiltration in chronic lymphocytic leukaemia: case report. Int J Clin Pract Suppl. 2005;147:53–5.PubMedCrossRef
26.
Turkmen K, Altintepe L, Guney I, Aydogdu I, Koc O, Erkut MA, et al. Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient. Int J Nephrol Renovasc Dis. 2010;3:65–8.PubMedCentralPubMedCrossRef
Metadata
Title
Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome in children with hematological malignancies
Authors
Daisuke Suzuki
Ryoji Kobayashi
Akihiro Iguchi
Hirozumi Sano
Kenji Kishimoto
Kazue Yasuda
Kunihiko Kobayashi
Publication date
01-11-2014
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1658-z

Other articles of this Issue 5/2014

International Journal of Hematology 5/2014 Go to the issue

Original Article

Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens

Case Report

Anti-erythropoietin receptor antibody-associated pure red cell aplasia accompanied by Coombs-negative autoimmune hemolytic anemia in a patient with T cell/histiocyte-rich large B cell lymphoma

Rapid Communication

Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy

Original Article

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms

Original Article

Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience

Letter to the Editor

Clostridium difficile infection: an undeniably common problem among hematopoietic transplant recipients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits